A First in Human Study to Assess the Safety, Tolerability of LB54640 in in Healthy Overweight and Obese Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

112

Participants

Timeline

Start Date

March 16, 2020

Primary Completion Date

March 30, 2022

Study Completion Date

July 30, 2022

Conditions

ObeseOverweightHealthy

Interventions

DRUG

LB64640

The investigational product (IP) LB54640 is provided 5 mg, 25 mg and 200 mg strengths.

DRUG

Placebo

Placebo is provided as a matching placebo

Trial Locations (1)

Clinical Research Unit, Chula Vista